HeartBeam has announced a commercial partnership with ClearCardio, a preventive cardiology practice, marking the medical technology company's first commercial customer. The agreement includes a planned investment by ClearCardio in HeartBeam and outlines a staged rollout to integrate HeartBeam's synthesized 12-lead ECG technology into ClearCardio's cardiac prevention programs for arrhythmia assessment. Structured as a Letter of Intent with subscription-based commercial terms and a collaborative deployment plan, the agreement supports HeartBeam's broader growth strategy.
The partnership enables patients to capture clinical-grade ECG readings from home using HeartBeam's patented cable-free 3D ECG system. This technology, which received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025, is designed to collect ECG signals from three non-coplanar directions and synthesize them into a 12-lead ECG. The platform allows physicians to identify cardiac health trends and acute conditions outside traditional medical facilities. The integration represents a significant step in transforming cardiac care by making advanced monitoring accessible outside clinical settings.
ClearCardio serves thousands of patients through heart health screening and personalized prevention programs, positioning the partnership to potentially impact a substantial patient population seeking preventive cardiac care. This expansion into concierge care and preventive cardiology networks aligns with HeartBeam's continued development of its 12-lead ECG patch monitor and advancement of AI-driven cardiac care initiatives. The company holds over 20 issued patents related to its technology enablement. Additional information about the company is available in its newsroom at https://ibn.fm/BEAT.
